Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | 13-year follow up results of the SOFT and TEXT trials in ILC

Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, comments on the follow-up results from the Phase III TEXT (NCT00066703) and SOFT (NCT00066690) trials, which investigated the efficacy of exemestane plus ovarian function suppression compared to tamoxifen in premenopausal women with invasive lobular carcinoma (ILC). Ovarian function suppression provided a more significant benefit in invasive lobular carcinoma (ILC) than invasive ductal carcinoma (IDC). This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.